onc Videos

Videos

Videos

Role of Minimal Residual Disease in the Management of CLL: How Do We Use it and When?

11/15/2022

Othman Al-Sawaf, MD, provides insight into the best use of minimal residual disease in the management of patients with CLL, which he presented at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Othman Al-Sawaf, MD, provides...

11/15/2022

Oncology

Videos

BTK Inhibitors vs BCL-2 Inhibitors as Frontline Therapy for Patients With CLL

11/14/2022

Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Asher Chanan-Khan, MD, argues in...

11/14/2022

Oncology

Videos

Novel Antibody Drug Conjugates for Triple-Negative Breast Cancer

11/14/2022

Komal Jhaveri, MD, provides insights and information regarding new and emerging antibody drug conjugate therapies for patients with triple-negative breast cancer, a topic she presented at the 2022 Great Debates & Updates in Women’s Oncology...

Komal Jhaveri, MD, provides...

11/14/2022

Oncology

Videos

New and Emerging Targeted Agents for CLL: A Review of Available BTK Inhibitors

11/14/2022

Jan Burger, MD, discusses relevant genetic mutations in CLL which may influence treatment decisions and reviews safety and efficacy data on new and emerging targeted agents for these patients, focusing on BTK inhibitors.

Jan Burger, MD, discusses...

11/14/2022

Oncology

David Cescon, MD, Princess Margaret Cancer Center

Videos

CDK4/6 Inhibitors Exhibit Similarities in Progression-Free Survival for Metastatic ER-Positive/HER2-Negative Breast Cancer

11/14/2022

David Cescon, MD, PhD, discusses the similarities and differences in CDK4/6 inhibitors for patients with breast cancer, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.

David Cescon, MD, PhD, discusses...

11/14/2022

Oncology

Alvaro Arjona-Sanchez, MD, Hospital Universitario Reina Sofia

Videos

Adjuvant HIPEC Before Resection Improves Locoregional Control in Patients With Locally Advanced Colon Cancer

11/14/2022

Alvaro Arjona-Sanchez, MD, explains findings from a phase 3 studyshowing HIPEC combined with mitomycin C, administered prior to surgical resection for locally advanced colon cancer, led to an improvement in locoregional control rate.

Alvaro Arjona-Sanchez, MD,...

11/14/2022

Oncology

Videos

Tremelimumab Added to Durvalumab and Chemotherapy Demonstrates Long-Term OS Benefit in Metastatic NSCLC

11/11/2022

Melissa Johnson, MD, discusses an OS update from the POSEIDON trial after a median follow-up of approximately 4 years, showing a durable long-term OS benefit by adding tremelimumab to durvalumab and chemotherapy for patients with metastatic...

Melissa Johnson, MD, discusses...

11/11/2022

Oncology

Michel Ducreux, MD, Gustave Roussy Cancer Center

Videos

FOLFIRINOX Prolongs PFS vs Gemcitabine for Patients With Unresectable Pancreatic Cancer

11/10/2022

Michel Ducreux, MD, reports results from a phase 3 trial showing FOLFIRINOX chemotherapy yields a significantly longer PFS vs gemcitabine for patients with locally advanced, unresectable pancreatic cancer.

Michel Ducreux, MD, reports...

11/10/2022

Oncology

Ana Aparicio, MD, MD Anderson Cancer Center

Videos

Treatment Approaches for Aggressive Variants of Metastatic Castration-Resistant Prostate Cancer

11/10/2022

Ana Aparicio, MD, discusses aggressive variants of metastatic castration-resistant prostate cancer, with a focus on treatment approaches for patients with androgen-indifferent disease.

Ana Aparicio, MD, discusses...

11/10/2022

Oncology

Stephane Oudard, MD, Hôpital Européen Georges-Pompidou

Videos

Adapted Cabazitaxel Schedule Reduces Neutropenic Complications in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer

11/10/2022

Stéphane Oudard, MD, reports results from a phase 3 trial demonstrating that an adapted schedule of cabazitaxel reduces neutropenic complications seen in elderly patients with metastatic castration-resistant prostate cancer without...

Stéphane Oudard, MD, reports...

11/10/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology